Here’s our list of the 15 finest, plus another half dozen honorable mentions. In an age of music streaming, these places have ...

Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation company, today announced that initial Phase 1 clinical results with PLX-4545, a selective IKZF2 molecular glue degrader, ...

In Wayne Gretzky's hometown of Brantford, Ontario, and across Canada, the Great One's loyalty and legacy are being questioned ...

AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026 Multiple ...

The former IWGP Heavyweight Champion will have his final match in the US at Windy City Riot against the current NEVER ...

Dewpoint will present two posters at AACRCondensate modulators (c-mods) demonstrate robust anti-tumor effects across multiple ...

Additional data from the MDNA11 ABILITY-1 trial to be presented at the Annual Meeting. Pre-clinical data on Medicenna’s first-in-class Masked and Tumor Targeted Bifunctional ant ...

– Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and cabozantinib in patients with RCC in 2H 2025 – ...

One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327 ...

KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapy programs, today announced the upcoming presentation of a ...